HENDERSON, Nev., Aug. 3, 2022
/PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX)
("Volition"), a multi-national epigenetics company, has announced
it has been awarded a further $1.5
million non-dilutive funding from Namur Invest Capital Risk
in Belgium.
Namur Invest's award will fund an early access program for
Volition's Nu.Q® product portfolio at key sites across the EU, UK,
and USA.
Gaetan Michel, Chief Operating
Officer of Volition, said: "Thanks to this latest funding from
Namur Invest we are incredibly excited to launch our early access
program and engage industry leaders in the development and adoption
of our transformative Nucleosomics™ technology in a range of
exemplifications of our assays.
"We will be working with centers of excellence worldwide
providing leading clinicians and researchers with exclusive, early
access to our Nu.Q® product range. This is an enormous step forward
for Volition and a critical phase in our path to commercialization.
We would like to thank Renaud Hattiez and his team at Namur
Invest for their continued support."
Renaud Hattiez, Director General of Namur Invest, said: "We have
supported Volition since its inception and wholeheartedly believe
in the company's mission to revolutionize the diagnosis and
monitoring of life-altering diseases. We are delighted to support
Volition on the next step of its journey, engaging Key Opinion
Leaders from across the globe and bringing Nu.Q® to fruition."
Namur Invest's loan is the latest grant from agencies within the
Walloon Region, amounting to more than $14
million in non-dilutive funding since 2016. The new
$1.5 million (Euro 1.5 million) loan to fund Volition's early
access program is unsecured, bears interest at a rate of 6% per
year and is repayable over four years with a maturity date of
July 31, 2026.
Volition is developing simple, easy-to-use, cost-effective blood
tests to help diagnose and monitor a range of life-altering
diseases in both humans and animals. For more information about
Volition's Nu.Q® technology go to: www.volition.com
About Volition
Volition is a multi-national epigenetics company that applies
its Nucleosomics™ platform through its subsidiaries to develop
simple, easy to use, cost effective blood tests to help diagnose
and monitor a range of life-altering diseases including some
cancers and diseases associated with NETosis such as sepsis and
COVID-19. Early diagnosis and monitoring have the potential to not
only prolong the life of patients but also improve their quality of
life. The tests are based on the science of Nucleosomics™, which is
the practice of identifying and measuring nucleosomes in the
bloodstream or other bodily fluid - an indication that disease is
present. Volition is primarily focused on human diagnostics and
monitoring but also has a subsidiary focused on animal diagnostics
and monitoring.
Volition's research and development activities are centered in
Belgium, with an innovation
laboratory and office in the U.S. and additional offices in
London and Singapore.
The contents found at Volition's website address are not
incorporated by reference into this document and should not be
considered part of this document. The address for Volition's
website is included in this document as an inactive textual
reference only.
Volition Enquiries:
Louise
Batchelor/Debra Daglish,
Volition, mediarelations@volition.com , +44 (0)7557 774620
Safe Harbor Statement
Statements in this press release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends,"
"plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "could," "would,"
"should," "may," "will" and similar expressions identify
forward-looking statements. These forward-looking statements relate
to, among other topics, the use of proceeds from the additional
funding, the launch and success of Volition's early access program,
, and expectations related to the potential uses, benefits and
effectiveness of Volition's Nu.Q® products. Volition's actual
results may differ materially from those indicated in these
forward-looking statements due to numerous risks and uncertainties,
including, without limitation, a failure by the marketplace to
accept Volition's Nu.Q® tests; Volition's failure to secure
adequate intellectual property protection; Volition will face
fierce competition and its intended products may become obsolete
due to the highly competitive nature of the diagnostics and disease
monitoring markets and their rapid technological change; downturns
in domestic and foreign economies; and other risks identified in
Volition's most recent Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q, as well as other documents that Volition
files with the Securities and Exchange Commission. These statements
are based on current expectations, estimates and projections about
Volition's business based, in part, on assumptions made by
management. These statements are not guarantees of future
performance and involve risks, uncertainties and assumptions that
are difficult to predict. Forward-looking statements are made as of
the date of this release, and, except as required by law, Volition
does not undertake an obligation to update its forward-looking
statements to reflect future events or circumstances.
Nucleosomics™ and Nu.Q® and their respective logos are
trademarks and/or service marks of VolitionRx Limited and its
subsidiaries. Additionally, unless otherwise specified, all
references to "$" refer to the legal currency of the United States of America.
View original
content:https://www.prnewswire.com/news-releases/volitionrx-awarded-1-5-million-in-non-dilutive-funding-301597312.html
SOURCE VolitionRx Limited